FOXO3 and idiopathic pulmonary fibrosis: Partial pharmacological restoration of FoxO3 activity can attenuate the IPF myofibroblast phenotype in vitro and bleomycin‐induced lung fibrosis in vivo, illuminating a potential therapeutic strategy.